Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. - Wikidata - wikimedia - TriplyDB

Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance.

Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance.

http://www.wikidata.org/entity/Q36369913

about

Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1 Tumor masses support naive T cell infiltration, activation, and differentiation into effectors Age-dependent tolerance to an endogenous tumor-associated antigen.Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.Different toll-like receptor stimuli have a profound impact on cytokines required to break tolerance and induce autoimmunity Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors.Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantation Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvant Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.Challenges and future perspectives of T cell immunotherapy in cancer TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice.Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression PKCtheta signals activation versus tolerance in vivo Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.Immune resistance orchestrated by the tumor microenvironment.The tumor-draining lymph node as an immune-privileged site.Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness.Mobilizing the low-avidity T cell repertoire to kill tumors.Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer.Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes.Immunological perspective of self versus tumor antigens: insights from the RIP-gp model.Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment.Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation.Cancer and the Immune System: Basic Concepts and Targets for Intervention.Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.Caspase-3-dependent beta-cell apoptosis in the initiation of autoimmune diabetes mellitus.Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice.Lack of IL-7 and IL-15 signaling affects interferon-γ production by, more than survival of, small intestinal intraepithelial memory CD8+ T cells.Making and circumventing tolerance to cancer.Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells.Mechanisms of tolerance.TCR affinity and negative regulation limit autoimmunity

P2860

Q24648492-D3546D47-A0CB-415A-AEAA-47A5531BE514 Q30433292-8814B2B1-7CC4-4BE6-A86E-A15717680D6B Q30439993-779BF31B-EE4F-4D5A-95B3-A8603CF9882D Q33756662-CD94A2AE-B145-459B-950B-7A47CA92EF3A Q34023191-06BC1DB4-8DFE-469D-9C62-CC255C165DC6 Q34071227-44206625-9A02-474B-AB5B-D40F5C4676AC Q34755544-CA3B07E9-DD7E-4729-9862-6021E62ABE5D Q34991001-F55D4655-C9F3-44E3-A9B2-11F89B2C8EAC Q35012887-3893F7B1-50D1-4FC9-838D-AD819A65E3C2 Q35125382-230274C2-6B4C-4278-BD74-46DFC7C45D5C Q35641792-B5DFEF2A-0C5A-4D93-82BB-E34F6B0764F6 Q35835489-DEA01173-67A9-48EB-9C70-F5301FE1E566 Q35843507-D8935CA1-BBD2-4416-B312-C7F330ED9448 Q36121743-EBFAE014-68EC-44AD-B534-3F91D57EDCE2 Q36371632-50BBAC3B-149F-4EAC-AEDE-4702DAD477C2 Q36399807-6EF6D467-C1A2-48CD-8E52-5DFC9E4221FE Q36402354-D151977C-B940-4C96-98F4-302946BAA118 Q36471604-E1807058-51E1-47AC-B8B8-A4B3CCFF1845 Q36593747-71C23713-3E15-496A-8334-CC918B529ECB Q36593753-7AF62592-405B-4E01-A2F4-C824EB982C4B Q36742295-A45A40B7-933A-44F3-A407-1F2FAE98BED9 Q36891310-17DB2F48-67DA-4F94-9F3B-93C2EE7A1CDE Q37001690-8BE998B7-5087-4E33-8400-A33F4B1CC3C5 Q37055402-5AA3AA1E-7159-45A2-9CFA-E241D3B1CBC2 Q37114367-514FA906-F5DC-4B94-9CFE-5F788FD45D11 Q37286396-9E1BF25E-BD74-4C97-9BE7-DA6D6E55EF8B Q37290676-3800D025-8559-47BF-B21B-1EB753762DFE Q37864698-3E0370CF-E822-4DBB-A2B5-2C0225CC4F21 Q38031760-57786AFB-6234-45C9-AC06-9023166BF8F5 Q38088635-72AD3409-CDCA-4667-BE1D-F1BBBAD5FE1E Q38576504-0742FE0D-07B3-44D1-B660-C72D5B6F8CED Q38779877-0341D1F0-C29B-4E7F-A066-83C88B23873D Q39815528-9A3CF2E5-2A66-466C-B92C-BCE68213DBD3 Q42724764-2BEB7BD7-985E-4B73-92BD-75492B95840C Q43108657-5FCD31D3-474F-47B5-A1D4-395171BDFC81 Q50991984-0A83FCEC-DC92-453C-A57E-02D4490733F2 Q52909563-84D5FE97-E57E-4730-9EBF-F7C100DCDD1F Q53493928-D2D29886-2695-452B-8697-1F6BCE944F23 Q53906830-1F0E5311-F9B2-4562-9DA0-6DF45AF7FDF9 Q57184989-CB1DFEA3-67EE-4215-B203-C97EF8DD93FD

P2860

Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance.

http://www.wikidata.org/entity/Q36369913

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Tumor growth enhances cross-pr ...... activation without tolerance.

@ast

Tumor growth enhances cross-pr ...... activation without tolerance.

@en

type

label

Tumor growth enhances cross-pr ...... activation without tolerance.

@ast

Tumor growth enhances cross-pr ...... activation without tolerance.

@en

prefLabel

Tumor growth enhances cross-pr ...... activation without tolerance.

@ast

Tumor growth enhances cross-pr ...... activation without tolerance.

@en

P1433

Q36369913-9ECB784E-37BE-402F-BCFA-E73F5C3820D6

P1476

Q36369913-9E8C00A0-8858-4280-972F-2B78936C6854

P2093

Q36369913-0A0AC7FA-A36E-4DCC-99E2-2E01D41EBFEA

Q36369913-58084364-352B-40BE-9B54-C3A44331812A

Q36369913-988136FE-3104-47E5-A743-3ED3C560A3CB

Q36369913-9E159541-44D1-4E75-8E9B-E38D732F9752

Q36369913-A68D636C-AFDE-491F-BB29-F9A0FF081CD2

Q36369913-E48BD8D9-2627-4CEF-9CC0-B7366BBB4CC8

Q36369913-F1279B18-0F51-4DE7-8EF6-6AC49ADFA85D

P2860

Q36369913-0418D74F-B19A-404F-B6EB-6EF6BD2ED2BA

Q36369913-04BFA22C-949F-43F2-88DE-D522EA5752ED

Q36369913-0D3CF66E-DDF6-4E49-8783-E338302301CA

Q36369913-1F6FA199-79AB-448E-B73A-26878C2248F2

Q36369913-21764D20-F607-4D7B-86C6-BB11E8F9D7A4

Q36369913-25C8CD72-C865-4546-8A9A-0371F66FA9CF

Q36369913-26E3B206-9FD0-4878-9A5B-9C43F391370F

Q36369913-29C9C43E-B31F-4DE3-8793-E6C6E560CCBF

Q36369913-32210EDF-A622-4E94-AEB1-37B679369000

Q36369913-358E215C-E5FF-4FAA-9C23-277D4774FBFA

P304

Q36369913-89B004DC-AC69-4EC1-B56E-6F1A4DAD4CCC

P31

Q36369913-DDC633EF-1B89-4593-8BBF-534859EB5DF7

P356

Q36369913-F2D762AC-B0A7-4C39-8037-D2345278E634

P407

Q36369913-E95E1246-7631-406D-B675-2CC8E23F6789

P433

Q36369913-8388E84D-06EC-4508-BFC3-7FBAEEA21968

P478

Q36369913-F6814E22-CCC9-46A5-B5F7-957C8BACE186

P50

Q36369913-ddd65d87-4998-a8f1-f082-8e198e147641

P577

Q36369913-D92E004A-7FCE-4965-A669-7853D40189C6

P5875

Q36369913-498B5CD1-1450-42D2-BA30-9F742B8B1DC4

P698

Q36369913-C65ED2D6-2001-42D4-AA3B-F21EF684E1FA

P932

Q36369913-D602ACC8-4BD0-415A-90F5-D3E73713D055

P356

P1433

Journal of Experimental Medicine

P1476

Tumor growth enhances cross-pr ...... activation without tolerance.

@en

P2093

Alisha R Elford

http://www.w3.org/2001/XMLSchema#string

Bernhard Odermatt

http://www.w3.org/2001/XMLSchema#string

Daniel E Speiser

http://www.w3.org/2001/XMLSchema#string

Kiichi Murakami

http://www.w3.org/2001/XMLSchema#string

Kristine M Garza

http://www.w3.org/2001/XMLSchema#string

Linh T Nguyen

http://www.w3.org/2001/XMLSchema#string

Pamela S Ohashi

http://www.w3.org/2001/XMLSchema#string

P2860

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells

Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

Dendritic cells and the control of immunity

A new era for cancer immunotherapy based on the genes that encode cancer antigens

Immunobiology of dendritic cells

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo

Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy

Dendritic cell vaccines for cancer immunotherapy.

P304

423-435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20010032

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

195

http://www.w3.org/2001/XMLSchema#string

P50

Stephen Schoenberger

P577

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273550750

http://www.w3.org/2001/XMLSchema#string

P698

11854356

http://www.w3.org/2001/XMLSchema#string

P932

2193619

http://www.w3.org/2001/XMLSchema#string